Publications
707
Citations
22,344
Est. group size
~31
Recurring co-author estimate
Active years
49
Publishing since 1978
David E. Cohn's research focuses on gynecologic cancers, especially ovarian, endometrial, and cervical cancer, with an emphasis on clinical trials of new drug combinations, genomic and proteomic profiling of tumors, and analysis of treatment outcomes across patient populations. Much of the work involves large multi-institutional clinical trials (e.g., NCI/NRG-Oncology studies) and translational research linking tumor biology to therapy response. This profile suggests opportunities for students interested in clinical/translational oncology research, biomarker discovery, and cancer clinical trial design.
Publication output has fluctuated over the past decade, with a notable spike in 2023 followed by a return to more moderate, steady annual output in recent years.
Generated by claude-sonnet-5 from public bibliographic data · Jul 20, 2026
- Operational Excellence in Cancer Care
Journal of the National Comprehensive Cancer Network · 2026
- Supplementary Table S3 from Randomized Phase II Study of Bevacizumab with Weekly Anetumab Ravtansine or Weekly Paclitaxel in Platinum-Resistant/Refractory High-Grade Ovarian Cancer (NCI Trial)
2025
- Supplementary Data S1 from Randomized Phase II Study of Bevacizumab with Weekly Anetumab Ravtansine or Weekly Paclitaxel in Platinum-Resistant/Refractory High-Grade Ovarian Cancer (NCI Trial)
2025
- Data from Randomized Phase II Study of Bevacizumab with Weekly Anetumab Ravtansine or Weekly Paclitaxel in Platinum-Resistant/Refractory High-Grade Ovarian Cancer (NCI Trial)
2025
- Supplementary Figure S1 from Randomized Phase II Study of Bevacizumab with Weekly Anetumab Ravtansine or Weekly Paclitaxel in Platinum-Resistant/Refractory High-Grade Ovarian Cancer (NCI Trial)
2025
- Supplementary Table S1 from Randomized Phase II Study of Bevacizumab with Weekly Anetumab Ravtansine or Weekly Paclitaxel in Platinum-Resistant/Refractory High-Grade Ovarian Cancer (NCI Trial)
2025
- Supplementary Table S2 from Randomized Phase II Study of Bevacizumab with Weekly Anetumab Ravtansine or Weekly Paclitaxel in Platinum-Resistant/Refractory High-Grade Ovarian Cancer (NCI Trial)
2025
- Supplementary Figure S3 from Randomized Phase II Study of Bevacizumab with Weekly Anetumab Ravtansine or Weekly Paclitaxel in Platinum-Resistant/Refractory High-Grade Ovarian Cancer (NCI Trial)
2025
- Supplementary Figure S2 from Randomized Phase II Study of Bevacizumab with Weekly Anetumab Ravtansine or Weekly Paclitaxel in Platinum-Resistant/Refractory High-Grade Ovarian Cancer (NCI Trial)
2025
- Randomized Phase II Study of Bevacizumab with Weekly Anetumab Ravtansine or Weekly Paclitaxel in Platinum-Resistant/Refractory High-Grade Ovarian Cancer (NCI Trial)
Clinical Cancer Research · 2025
- Author Correction: Proteogenomic analysis of enriched HGSOC tumor epithelium identifies prognostic signatures and therapeutic vulnerabilities
npj Precision Oncology · 2024
- Proteogenomic analysis of enriched HGSOC tumor epithelium identifies prognostic signatures and therapeutic vulnerabilities
npj Precision Oncology · 2024
- Data from Profiling Microdissected Epithelium and Stroma to Model Genomic Signatures for Cervical Carcinogenesis Accommodating for Covariates
2023
- Supplementary Tables 1-2, Methods and Figures 1-2 from Profiling Microdissected Epithelium and Stroma to Model Genomic Signatures for Cervical Carcinogenesis Accommodating for Covariates
2023
- Data from Profiling Microdissected Epithelium and Stroma to Model Genomic Signatures for Cervical Carcinogenesis Accommodating for Covariates
2023
- Gynecologic Oncology×150
- Journal of Clinical Oncology×15
- Cancer Research×14
- Journal of the National Comprehensive Cancer Network×8
- Gynecologic Oncology Reports×8
- Casey Cosgrove
Medicine · The Ohio State University
- Jessica Velasquez
Medicine · The Ohio State University
- Floor Backes
Medicine · The Ohio State University
- Kristin Bixel
Medicine · The Ohio State University
- Adrian A. Suarez
Medicine · The Ohio State University
This profile was generated automatically from public scholarly data (OpenAlex). Group size and activity levels are estimates derived from co-authorship patterns.
Last updated Jul 19, 2026.
Claim or correct this profile